Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
August 02 2017 - 10:00AM
Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for respiratory diseases,
announces today that it will report its interim results for the six
months ended June 30, 2017 on Tuesday, August 8, 2017.
Verona Pharma will host an investment community
conference call at 8:00 a.m. Eastern Daylight Time (1:00 pm British
Summer Time) on August 8, 2017 to discuss the interim financial
results and provide a clinical development update.
Analysts and investors may participate in the
conference call by utilizing the conference ID: 4729485 and dialing
the following numbers:
- (877)280-2296 or (646)254-3367 for callers in the United
States
- 0800 279 4841 or 44(0)20 3427 1905 for callers in the United
Kingdom
- 0800 589 2674 or 49(0)69 2222 10624 for calls in Germany
Those interested in listening to the conference
call live via the internet may do so by visiting the “Investors”
page of Verona Pharma’s website at www.veronapharma.com and
clicking on the webcast link.
A webcast replay of the conference call [audio]
will be available on the “Investors” page of Verona Pharma’s
website at www.veronapharma.com.
About Verona Pharma plc
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of respiratory diseases with
significant unmet medical needs.
Verona Pharma’s product candidate, RPL554, is a
first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 that acts as both a bronchodilator and an
anti-inflammatory agent in a single compound. Verona Pharma is
developing RPL554 for the treatment of chronic obstructive
pulmonary disease (COPD) and cystic fibrosis (CF), and potentially
asthma.
For further information, please
contact:
Verona Pharma plc |
Tel:
+44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer |
info@veronapharma.com |
|
|
N+1
Singer (Nominated Adviser and UK Broker) |
Tel:
+44 (0)20 7496 3000 |
Aubrey Powell / James White / Alex Laughton-Scott |
|
|
|
FTI
Consulting (UK Media and Investor enquiries) |
Tel:
+44 (0)20 3727 1000 |
Simon
Conway / Stephanie Cuthbert / Natalie Garland-Collins |
veronapharma@fticonsulting.com |
|
|
ICR,
Inc. (US Media and Investor enquiries) |
|
James
Heins |
Tel:
+1 203-682-8251 |
|
James.Heins@icrinc.com |
Stephanie Carrington |
Tel.
+1 646-277-1282 |
|
Stephanie.Carrington@icrinc.com |
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More News Articles